Paxlovid™ (nirmatrelvir/ritonavir) – Emergency use authorization
December 22, 2021 - The FDA announced the emergency use authorization (EUA) approval of Pfizer’s Paxlovid (nirmatrelvir/ritonavir), for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death.
Top